Other clinically important example of genes’ cloning into CRC PDOs is the importance of BRAF fusions with different partners in regard to conferred resistance to targeted inhibition of the MAPK pathway, thus suggesting to include BRAF fusions in CRC patients’ genetic screening [162]. The gene discussed is BRAF; the disease is colorectal carcinoma.